XML 91 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION
SEGMENT AND GEOGRAPHIC INFORMATION
Starting in the first quarter of 2012, because of changes in how the Company internally manages and reports the results of its businesses to its chief operating decision maker, the Company began reporting five reportable segments. The five reportable segments and a description of their activities are described below:
•
The U.S. Neurosurgery segment sells a full line of products specifically for neurosurgery and critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
•
The U.S. Instruments business sells more than 60,000 instrument patterns and surgical products and lighting to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
•
The U.S. Extremities segment includes the U.S. extremity reconstruction business, which includes such offerings as skin and wound repair, bone and joint fixation, implants in the upper and lower extremities, bone grafts and nerve and tendon repair.
•
The U.S. Spine and Other segment includes (i) the U.S. Spine business, which focuses on spinal fusion, spinal implants, and deformity correction, together with bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in various types of orthopedic surgical procedures, and (ii) the Private Label business, which sells the Company’s regenerative medicine and other products to strategic partners.
•
The International segment sells similar products to those discussed above, but are managed through the following geographies: (i) Europe, Middle East and Africa, and (ii) Latin/South America, Asia-Pacific, Australia, New Zealand and Canada.
The Corporate and other category includes (i) various legal, finance, executive, and human resource functions, (ii) brand management, (iii) share-based compensation costs, and (iv) costs related to procurement, manufacturing operations and logistics for the Company’s entire organization.
Accordingly, the segment information for the prior years has been restated in accordance with authoritative guidance on segment reporting. The accounting policies of the reportable segments are the same as those described in Note 2.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results.
Net sales and profit by reportable segment for the years ended December 31, 2013, 2012 and 2011 are as follows:
 
 
Years Ended December 31,
 
2013
 
2012
 
2011
 
(In thousands)
Segment Net Sales
 
 
 
 
 
U.S. Neurosurgery
$
172,250

 
$
171,278

 
$
165,652

U.S. Instruments *
163,908

 
166,921

 
160,777

U.S. Extremities *
128,336

 
116,279

 
91,513

U.S. Spine and Other *
182,006

 
192,516

 
176,131

International
189,714

 
183,877

 
186,005

Total revenues
$
836,214

 
$
830,871

 
$
780,078

Segment Profit
 
 
 
 
 
U.S. Neurosurgery
$
83,211

 
$
91,070

 
$
86,206

U.S. Instruments *
49,348

 
50,277

 
46,281

U.S. Extremities *
47,880

 
43,952

 
32,905

U.S. Spine and Other *
10,136

 
57,388

 
52,248

International
56,869

 
61,336

 
64,164

Segment profit
247,444

 
304,023

 
281,804

Amortization
(12,697)

 
(18,536)

 
(16,433)

Corporate and other
(244,903
)
 
(211,705
)
 
(210,459
)
Operating income (loss)
$
(10,156
)
 
$
73,782

 
$
54,912


* Certain revenues and profits have been reclassified from the U.S. Extremities segment to the U.S. Instruments segment and the U.S. Spine and Other segment in each of the periods presented.
The Company does not allocate any assets to the reportable segments, and, therefore, no asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment.
Revenue by major product category consisted of the following: 
 
Years Ended December 31,
 
2013
 
2012
 
2011
 
(In thousands)
Orthopedics **
$
370,359

 
$
364,714

 
$
324,535

Neurosurgery
278,672

 
277,527

 
272,538

Instruments **
187,183

 
188,630

 
183,005

Total revenues
$
836,214

 
$
830,871

 
$
780,078



** Certain revenues have been reclassified from the Orthopedics category to the Instruments category in each of the periods presented.
The Company attributes revenue to geographic areas based on the location of the customer. There are certain revenues managed by the various U.S. segments above that are generated from non-U.S. customers and therefore included in Europe and the Rest of World revenues below.
Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:
 
United States*
 
Europe
 
Rest of the World
 
Consolidated
 
(In thousands)
Total revenue, net:
 
 
 
 
 
 
 
2013
$
642,694

 
$
93,977

 
$
99,543

 
$
836,214

2012
642,830

 
90,920

 
97,121

 
830,871

2011
589,946

 
97,184

 
92,948

 
780,078

Total long-lived assets:
 
 
 
 
 
 
 
2013
$
187,608

 
$
20,010

 
$
1,030

 
$
208,648

2012
166,508

 
20,242

 
1,507

 
188,257


* Includes long-lived assets in Puerto Rico.